SLC5A2 and metabolic syndrome: Our findings are consistent with previous studies that support the integration of microbiota-focused strategies in T2DM management and suggest that SGLT2 inhibitors like empagliflozin may hold a superior therapeutic profile for patients where gut dysbiosis and metabolic syndrome coexist [29].